Adherence to treatment of chronic hepatitis C: From interferon containing regimens to interferon and ribavirin free regimens

Medicine (United States)

Volumn 95, Issue 28, 2016, Pages

  Younossi, Zobair M ^a,c   Stepanova, Maria ^b   Henry, Linda ^b   Nader, Fatema ^b   Younossi, Youssef ^b   Hunt, Sharon ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

hepatitis C; interferon; quality of life; ribavirin; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; RNA; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; INTERFERON;

ADULT; ANEMIA; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; DEMOGRAPHY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; UNEMPLOYMENT; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC);

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FLUORENES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT REPORTED OUTCOME MEASURES; RIBAVIRIN; SOFOSBUVIR;

EID: 84979988396     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004151     Document Type: Article

References (40)

1. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med 2004;71(Suppl 3):S8-12.
2. Shehab TM, Fontana RJ, Oberhelman K, et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004;2:425-31.
3. Mravcík V, Strada L, Stolfa J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence 2013;7: 1067-75.
4. La Fleur J, Hoop R, Morgan T, et al. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes 2014;7:266.
5. Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005;12:81-5.
6. Jürgen K. Rockstroh M.D. Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? EASL 48th Annual Meeting. April 24th-28th, 2013 Amsterdam, ND.
7. Quelhas R, Lopes A. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009;15:262-81.
8. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am JManag Care 2005;11 (10 Suppl):S296-306.
9. Guadagnino V, Trotta MP, Carioti J, et al. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis 2006;38:119-24.
10. Price JC, Murphy RC, Shvachko VA, et al. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 2014;59:3043-52.
11. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014;12:1371-80.
12. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
13. Niederau C, Mauss S, Schober A, et al. Predictive factors for sustained virological response after treatment with pegylated interferon a-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One 2014;9:e107592.
14. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014;174:204-12.
15. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat 2005;12:91-5.
16. Les I, Doval E, Flavià M, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010;22: 221-7.
17. Rodis JL, Kibbe P. Evaluation ofmedication adherence and quality of life in patients with hepatitis c virus receiving combination therapy. Gastro Nurs 2010;33:368-73.
18. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53.
19. Bonner JE, Esserman DA, Golin CE, et al. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol 2015;49: 76-83.
20. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-7.
21. Sublette VA, Hopwood M, George J, et al. Instrumental support to facilitate hepatitis C treatment adherence: working around shortfalls in shared-care. Psychol Health Med 2015;20:186-97.
22. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
23. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53.
24. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
25. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
26. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370: 1483-93.
27. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
28. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
29. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014;61:228-34.
30. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-13.
31. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
32. Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999;8:604.
33. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
34. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
35. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on healthrelated quality of life in chronic hepatitis C. J Hepatol 2004;40:675-81.
36. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
37. Jerkeman A, Norkrans G, Lidman C, et al. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy. Eur J Gastroenterol Hepatol 2014;26:523-31.
38. Kallman J, O'Neil MM, Larive B, et al. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci 2007;52:2531-9.
39. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The chronic hepatitis cohort study (CHeCS). Hepatology 2015;61:802-11.
40. Terrault N, Monto A, Stinchon MR, et al. New therapies, evidence, and guidance in hepatitis C management: expert practices and insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo. J Manag Care Spec Pharm 2015;21:S1-7.